Multiple Sclerosis Centers Revise MRI Guidelines
The new guidelines are more sensitive to potential toxicity
The newly-revised guideline states – “Gadolinium-based contrast agents do accumulate in the brain and, to a much lesser degree with macrocyclic agents. While there is no known central nervous system toxicity, these agents should be used judiciously, recognizing that gadolinium continues to play an invaluable role in specific circumstances related to the diagnosis and follow-up of individuals with MS.” Since there are many different types of MS lesions, GBCAs show up in bright colors in lesions where active inflammation or disease activity is occurring. This, in turn, helps healthcare professionals track how active a patient’s MS is at the time and whether their treatment is working or requires any changes.
